Cargando…
Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities
This study aimed to evaluate the therapeutic efficacy of the cisplatin encapsulated into polybutylcyanoacrylate (PBCA) nanoparticles for the treatment of kidney cancer. The nanoformulation was successfully developed using the miniemulsion polymerization method and characterized in terms of size, siz...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151690/ https://www.ncbi.nlm.nih.gov/pubmed/32168743 http://dx.doi.org/10.3390/ph13030044 |
_version_ | 1783521307902607360 |
---|---|
author | Ghaferi, Mohsen Amari, Samar Vivek Mohrir, Bhalchandra Raza, Aun Ebrahimi Shahmabadi, Hasan Alavi, Seyed Ebrahim |
author_facet | Ghaferi, Mohsen Amari, Samar Vivek Mohrir, Bhalchandra Raza, Aun Ebrahimi Shahmabadi, Hasan Alavi, Seyed Ebrahim |
author_sort | Ghaferi, Mohsen |
collection | PubMed |
description | This study aimed to evaluate the therapeutic efficacy of the cisplatin encapsulated into polybutylcyanoacrylate (PBCA) nanoparticles for the treatment of kidney cancer. The nanoformulation was successfully developed using the miniemulsion polymerization method and characterized in terms of size, size distribution, drug loading and encapsulation efficiencies, drug release behavior, in vitro cytotoxicity effects, in vivo toxicity, and therapeutic effects. Cisplatin-loaded PBCA nanoparticles were confirmed to be in nanoscale with the drug entrapment efficiency of 23% and controlled drug release profile, in which only 9% of the loaded drug was released after 48 h. The nanoparticles caused an increase in the cytotoxicity effects of cisplatin against renal cell adenocarcinoma cells (ACHN) (2.3-fold) and considerably decreased blood urea nitrogen and creatinine concentrations when compared to the standard cisplatin (1.6-fold and 1.5-fold, respectively). The nanoformulation also caused an increase in the therapeutic effects of cisplatin by 1.8-fold, in which a reduction in the mean tumor size was seen (3.5 mm vs. 6.5 mm) when compared to the standard cisplatin receiver rats. Overall, cisplatin-loaded PBCA nanoparticles can be considered as a promising drug candidate for the treatment of kidney cancer due to its potency to reduce the side effects of cisplatin and its toxicity and therapeutic effects on cancer-bearing Wistar rats. |
format | Online Article Text |
id | pubmed-7151690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71516902020-04-20 Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities Ghaferi, Mohsen Amari, Samar Vivek Mohrir, Bhalchandra Raza, Aun Ebrahimi Shahmabadi, Hasan Alavi, Seyed Ebrahim Pharmaceuticals (Basel) Article This study aimed to evaluate the therapeutic efficacy of the cisplatin encapsulated into polybutylcyanoacrylate (PBCA) nanoparticles for the treatment of kidney cancer. The nanoformulation was successfully developed using the miniemulsion polymerization method and characterized in terms of size, size distribution, drug loading and encapsulation efficiencies, drug release behavior, in vitro cytotoxicity effects, in vivo toxicity, and therapeutic effects. Cisplatin-loaded PBCA nanoparticles were confirmed to be in nanoscale with the drug entrapment efficiency of 23% and controlled drug release profile, in which only 9% of the loaded drug was released after 48 h. The nanoparticles caused an increase in the cytotoxicity effects of cisplatin against renal cell adenocarcinoma cells (ACHN) (2.3-fold) and considerably decreased blood urea nitrogen and creatinine concentrations when compared to the standard cisplatin (1.6-fold and 1.5-fold, respectively). The nanoformulation also caused an increase in the therapeutic effects of cisplatin by 1.8-fold, in which a reduction in the mean tumor size was seen (3.5 mm vs. 6.5 mm) when compared to the standard cisplatin receiver rats. Overall, cisplatin-loaded PBCA nanoparticles can be considered as a promising drug candidate for the treatment of kidney cancer due to its potency to reduce the side effects of cisplatin and its toxicity and therapeutic effects on cancer-bearing Wistar rats. MDPI 2020-03-11 /pmc/articles/PMC7151690/ /pubmed/32168743 http://dx.doi.org/10.3390/ph13030044 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ghaferi, Mohsen Amari, Samar Vivek Mohrir, Bhalchandra Raza, Aun Ebrahimi Shahmabadi, Hasan Alavi, Seyed Ebrahim Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities |
title | Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities |
title_full | Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities |
title_fullStr | Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities |
title_full_unstemmed | Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities |
title_short | Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities |
title_sort | preparation, characterization, and evaluation of cisplatin-loaded polybutylcyanoacrylate nanoparticles with improved in vitro and in vivo anticancer activities |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151690/ https://www.ncbi.nlm.nih.gov/pubmed/32168743 http://dx.doi.org/10.3390/ph13030044 |
work_keys_str_mv | AT ghaferimohsen preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities AT amarisamar preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities AT vivekmohrirbhalchandra preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities AT razaaun preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities AT ebrahimishahmabadihasan preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities AT alaviseyedebrahim preparationcharacterizationandevaluationofcisplatinloadedpolybutylcyanoacrylatenanoparticleswithimprovedinvitroandinvivoanticanceractivities |